Medigen Vaccine Biologics Corporation (TPEX: 6547)

Market Cap	15.78B
Revenue (ttm)	623.45M
Net Income (ttm)	-694.03M
Shares Out	328.65M
EPS (ttm)	-2.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	999,627
Open	47.20
Previous Close	47.10
Day's Range	47.20 - 48.60
52-Week Range	39.55 - 77.50
Beta	0.77
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial fo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 103
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6547

Financial Performance

In 2023, Medigen Vaccine Biologics's revenue was 389.62 million, an increase of 6.73% compared to the previous year's 365.04 million. Losses were -1.16 billion, -21.34% less than in 2022.